Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

Gallbladder and Biliary Diseases

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU, Cobitz AR, Currie BM, Gorey C, Lazic I, Podmore D, Ribeiro A, Shannon JB, Swift B, McLaughlin MM, Levy C, GLISTEN Study Group

doi: 10.1016/S2468-1253(25)00192-X

Hepatitis

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Lancet

Noureddin M, Harrison SA, Loomba R, Alkhouri N, Chalasani N, Sheikh MY, Tomah S, Gutierrez JA, Urbina S, Suschak JJ, Brown R, Odili O, Yang J, Keeton S, Neff G, Mena E, Roberts MS, Browne SK, Harris MS

doi: 10.1016/S0140-6736(25)02114-2

Inflammatory Bowel Disease

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group

doi: 10.1016/S2468-1253(25)00322-X

Hepatology

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Lancet Gastroenterol Hepatol

Loomba R, George J, Castera L, Francque S, Lawitz E, Shoeb A, Clausen JO, Andersen B, Larsen AB, Gluud LL

doi: 10.1016/S2468-1253(26)00123-8

Inflammatory Bowel Disease

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Lancet Gastroenterol Hepatol

Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group

doi: 10.1016/S2468-1253(25)00198-0

Gastrointestinal Cancer

Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial

Lancet Gastroenterol Hepatol

Tuynman JB, Yao H, Moolenaar LR, Sietses C, Hompes R, Aigner F, Caycedo-Marulanda A, Chen CC, Deeb M, Doornebosch PG, Feng B, Foo CC, Fürst A, Ito M, de Lacy FB, Leão P, Maykel JA, Muratore A, van Oostendorp SE, Park SC, Pędziwiatr M, Ren M, Seitinger G, Stockmann HBAC, Talsma AK, Türler A, Tong W, Wang Q, Xu Q, Zhang H, van Waesberghe JTM, Ali M, Twisk JWR, Zhang Z, de Lacy AM, Hanna GB, Bonjer HJ, COLOR III Study Group

doi: 10.1016/S2468-1253(26)00022-1

Gastrointestinal Cancer

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

Lancet

Shen L, Zhang X, Ji K, Lu L, Wang Q, Guan Q, Yan S, Zhou Y, Yang Y, Huo Z, You J, Ba Y, Ye Y, Chen Y, Wang S, Lv G, Zhang J, Hu X, Yang F, Yu H, Li J, Wang Q, Zhu J, Ji J, ASTRUM-006 Study Group

doi: 10.1016/S0140-6736(26)00974-8

Esophagus Diseases

Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

Lancet Gastroenterol Hepatol

Takeuchi H, Machida R, Ando M, Tsubosa Y, Kikuchi H, Kawakubo H, Noma K, Ueno M, Tsushima T, Bamba T, Fujita T, Hamai Y, Kakishita T, Daiko H, Koyanagi K, Matsuda S, Kato K, Sasaki K, Kita R, Kitagawa Y, JCOG1409 investigators

doi: 10.1016/S2468-1253(25)00207-9

Inflammatory Bowel Disease

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

Reinisch W, Stepek D, Kempinski R, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Jairath V

doi: 10.1016/S2468-1253(26)00120-2

Related content

Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial

Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study

Thoracoscopic versus open oesophagectomy for patients with oesophageal cancer (JCOG1409 MONET): a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial